Login to Your Account

Wilex Rises on Potential $145M Prometheus Deal on Rencarex

By Cormac Sheridan

Wednesday, May 4, 2011
Shares in Wilex AG rose almost 20 percent Monday on news that the company secured $19 million up front and could bank another $20 million within 12 months as part of a U.S. deal with Prometheus Laboratories Inc. for its Phase III anticancer antibody Rencarex (girentuximab), which is potentially worth more than $145 million. (BioWorld International)

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription